LIR Life Sciences Corp.
SKNY
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | -1,840.75% | -359.93% | -207.23% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -- | -- | -- | ||
| Change in Net Operating Assets | -778.89% | 469.65% | 285.96% | ||
| Cash from Operations | -3,013.44% | 94.08% | -119.38% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | -- | -- | -44.00% | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -100.00% | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -100.00% | -- | -44.08% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -161.70% | 1,237.43% | -390.88% | ||